Early Clinical Detection of Pharmacologic Response in Insulin Action in a Non-diabetic Insulin Resistant Population
Conclusions Significant changes in insulin action across multiple insulin sensitive tissues can be detected within 2 weeks of initiation of insulin-sensitizing therapy with pioglitazone in obese non-diabetic insulin resistant subjects. Clinical Trial Registration Number NCT01115712.
Source: Current Therapeutic Research - Category: Drugs & Pharmacology Source Type: research
More News: Actos | Cardiology | Cardiovascular | Clinical Trials | Diabetes | Diabetes Mellitus | Diabetes Type 2 | Drugs & Pharmacology | Eating Disorders & Weight Management | Endocrinology | Heart | Insulin | Obesity | Study